Pierre Durozard
Ajaccio, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Differences in Use of Disease-Modifying Therapies Between Patients With Late-Onset and Adult-Onset Relapsing-Remitting Multiple Sclerosis.
Journal: Neurology
Published: May 05, 2026
Progression independent of relapse and MRI activity and treatment strategies in multiple sclerosis.
Journal: Brain : a journal of neurology
Published: July 21, 2025
Prevalence of hypogammaglobulinemia after non-anti-CD20 therapies and impact of switching to rituximab/ocrelizumab in multiple sclerosis.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: June 19, 2025
Diagnostic Utility of Kappa Free Light Chain Index in Adults With Inaugural Optic Neuritis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: March 14, 2025
Fluorescein Angiography as a Surrogate Marker of Disease Activity in Susac Syndrome.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: February 05, 2025
Extended-interval dosing of rituximab/ocrelizumab is associated with a reduced decrease in IgG levels in multiple sclerosis.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: October 15, 2024
Unveiling the Clinical and Imaging Signatures of Intravascular Lymphoma of the Central Nervous System: A Multicentric Cohort Study.
Journal: Annals of neurology
Published: August 07, 2024
Cortical Lesions as an Early Hallmark of Multiple Sclerosis: Visualization by 7 T MRI.
Journal: Investigative radiology
Published: June 18, 2024
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: April 16, 2024
Active and non-active progression independent of relapse activity within the first 20 years of relapsing multiple sclerosis.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: February 09, 2024
Control of disease activity with large extended-interval dosing of rituximab/ocrelizumab in highly active pediatric multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: January 03, 2024
Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: March 22, 2023
Last Updated: 09/26/2026